Biopharma split over Treasury China rule exemption for licensing deals

Treasury's proposed rule on China outbound investment includes an exemption for certain biopharma licensing deals, causing industry disagreement. The rule's scope and the exemption's terms remain unclear, and the split could shape final implementation and affect cross-border deal flows.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works